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Background: Patients with centrally located early lung cancer
(CLELC) are often heavy smokers with a considerably high risk of
multiple primary lung cancer (MPLC) lesions; treatment strategies
for such patients must preserve the cardiopulmonary function.
Methods: Between July 2004 and July 2008, patients with CLELC
underwent photodynamic therapy (PDT) using NPe6, second-gen-
eration photosensitizer at Tokyo Medical University Hospital.
Among these patients, we retrospectively analyzed MPLC, which
was treated by surgery plus PDT or PDT alone and examined the
effectiveness of PDT, and we propose a treatment strategy for
patients with MPLC.
Results: A total of 64 patients with CLECL received NPe6-PDT,
and MPLCs were found in 22 patients (34.4%) using sputum
cytology and a bronchoscopical examination using autofluorescence
bronchoscopy. Among these 22 patients, 10 patients underwent
surgery for primary lung cancer and underwent NPe6-PDT for the
treatment of secondary primary CLELC, one patient underwent PDT
for CLELC as a primary lesion followed by an operation for
peripheral-type lung cancer as a secondary primary lesion, and 11
patients underwent PDT alone for MPLC lesions (28 lesions) that
were roentgenographically occult lung cancers. Among these 22
patients with MPLC including peripheral-type lung cancers, which
were resected by surgery, all 39 CLELC lesions exhibited a com-
plete response after PDT, and all patients were alive.
Conclusions: For patients with lung cancer with a long-term history
of smoking, careful follow-up examinations after surgical resection
are needed considering the incidence of metachronous primary lung
cancers. PDT can play an important role for the treatment strategy
for MPLC.
Key Words: Multiple primary lung cancer, Photodynamic therapy,
Centrally located early lung cancer.
(J Thorac Oncol. 2010;5: 62–68)
Photodynamic therapy (PDT) is widely used as a treatmentoption for solid cancers and also for some noncancerous
diseases.1–3 Early lung cancers can be divided into two
categories, the peripheral type and the central type, according
to the site of origin of the tumor.4,5 In Japan, PDT is
recommended as a treatment option for centrally located early
lung cancers (CLELCs), which are roentgenographically oc-
cult squamous cell carcinomas not located distal to the
segmental bronchi that are histologically determined to be
carcinoma in situ or carcinoma showing only limited inva-
sion, with no evidence of invasion beyond the bronchial
cartilage, as defined in the therapeutic guidelines for lung
cancer established by the Japanese Ministry of Health, Labor
and Welfare based on the principles of evidence-based med-
icine.4,5 The second-generation photosensitizer talaporfin so-
dium (NPe6 or Laserphyrin), which has a major absorption
band at 664 nm, has been approved by the Japanese govern-
ment for use in the diagnosis/treatment of CLELC.4–7 A
phase II clinical study using NPe6 and a diode laser for
early-stage lung cancer demonstrated excellent antitumor
effects and safety, including a significantly lower skin inci-
dence of photosensitivity compared with that observed using
Photofrin (Wyeth Japan K.K., Tokyo, Japan).6,7 The Japanese
government approved the use of NPe6 for PDT in 2003, and
the product has been available in Japan since June 2004.4–7
Roentgenographically occult lung cancers, which are
located in the central bronchus, can be detected in high-risk
patients using either sputum cytology or bronchoscopic eval-
uation.8–11 One to 4% of these patients have a synchronous
lung cancer, and the risk of a second lung cancer ranges from
1 to 25% per year.12–14 Some reports have revealed that 17%
of newly diagnosed early lung cancer cases have a synchro-
nous lesion.15,16
Multiple primary lung cancer (MPLC) is not an uncom-
mon event, and Nakata et al.17 reported that 7.9% of patients
with surgically resected non-small cell lung cancers and 8.4%
of patients with adenocarcinomas exhibited multiple lesions.
In 1975, Martini and Melamed18 outlined the criteria for
differentiating between MPLC and recurrence, and they pro-
posed that tumors were ‘synchronous’ when they were de-
tected or resected simultaneously and ‘metachronous’ when
the second tumor was found some time later. Recently, the
Department of Thoracic Surgery, Tokyo Medical University, Tokyo, Japan.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Jitsuo Usuda, MD, PhD, Department of Thoracic
Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku,
Tokyo 160-0023, Japan. E-mail: jusuda@tokyo-med.ac.jp
Copyright © 2009 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/10/0501-0062
Journal of Thoracic Oncology • Volume 5, Number 1, January 201062
incidence of MPLC has been increasing as a result of the
widespread use of early detection tools such as multislice
spiral computed tomography (CT) and fluorescence endos-
copy.12–15 Nevertheless, no guidelines have detailed rec-
ommendations for the selection and treatment of patients
with synchronous or metachronous MPLC.
In particular, patients with CLELC are often heavy
smokers and have a considerably high risk of a second
primary lung cancer; thus, these patients require treatment
that will preserve their cardiopulmonary function. It has been
reported that 70% of carcinoma in situ is not detected during
white-light bronchoscopy, and that the prevalence of syn-
chronous occult lesions after fluorescence bronchoscopy as-
sessment might be higher than the previously reported values
of 7 to 14%.8,19,20 Moreover, after the successful treatment of
a first occult cancer, as many as 5% of the metachronous
tumors detected per year might actually result from the
progressive evolution of synchronous, undetected early lung
cancers. For patients treated using PDT, we routinely perform
follow-up examinations using autofluorescence bronchos-
copy (SAFE-3000) to avoid missing occult lung cancers.4–7,21
In such patients with synchronous or metachronous MPLC,
PDT is an effective treatment that also preserves lung function
and is recommended in the evidence-based clinical practice
guidelines of the American College of Chest Physicians.4–7
In this study, we retrospectively analyzed MPLC with
CLELC lesions, which were treated by surgery plus PDT or
PDT alone, and examined the effectiveness of PDT for the
treatment of patients with CLELCs, and we propose a treat-
ment strategy for patients with MPLC.
MATERIALS AND METHODS
Photosensitizer
NPe6 (Meiji Seika, Tokyo, Japan) is a second-genera-
tion, water-soluble photosensitizer with a molecular weight
of 799.69 and a chlorine annulus; its highest absorption peak
occurs at a wavelength of 407 nm, and a second peak occurs
at a wavelength of 664 nm.4–7 NPe6 exhibits superior in
tumor affinity, compared with Photofrin, and is excited by
visible red light with a longer wavelength of 664 nm, en-
abling deeper and superior penetration into living tissues.4,22
Laser Unit
A diode laser (Matsushita Electric Industrial Co.,
Osaka, Japan) emitting continuous-wave laser light at a
wavelength of 664 nm was used as the light source for the
excitation of NPe6.4–7
Criteria for the Diagnosis of CLELC
Lung cancers not located distal to the segmental bron-
chi, diagnosed histologically as squamous cell carcinoma,
and determined to be carcinoma in situ or carcinoma showing
only limited invasion with no evidence of invasion beyond
the bronchial cartilage were defined as CLELCs.4–7 We
routinely determined the tumor depth using endobronchial
ultrasonography and confirmed that the tumors had not in-
vaded the bronchial wall beyond the level of the cartilage and
were confined to the basal membrane of the mucosa, submu-
cosa, or intracartilaginous layers of the bronchial wall.4,5,7,23
In 2003, the Japan Photodynamic Association and Japanese
Society of Laser Surgery and Medicine established the fol-
lowing therapeutic criteria for PDT in cases with CLELC:
patients with (a) endoscopically assessable early lung cancer,
(b) a normal chest x-ray and CT, and (c) no metastasis to
lymph nodes or distant metastasis as revealed using routine
clinical diagnostic methods, including fluorodeoxyglucose-
position emission tomography for staging.4,5
PDT Procedures and Follow-Up
Local anesthesia was performed using 4% lidocaine
spray. Additional sedation was necessary. Laser irradiation
(664 nm) for NPe6-PDT was transmitted by means of quartz
fibers inserted through the biopsy channel of the endoscope,
4 to 6 hours after the administration of the photosensitizer,
NPe6 (40 mg/m2). The total energy of the laser irradiation
was 100 J/cm2 (150 mW/cm2).4–7 The Japanese government
approved the use of NPe6 for PDT against CLELCs in 2003,
and the product became available in Japan in June 2004.4–7
Ever since, we have used NPe6 for PDT. A fiber-optic
bronchoscopy with cytologic and histologic examinations
was performed at 1, 2, and 3 months after the PDT and at
3-month intervals during the first year and 6-month intervals
during the second year thereafter. The antitumor effect of the
initial treatment was rated based on the endoscopic measure-
ment of the tumor size using forceps, the morphologic ap-
pearance, and the pathologic findings of the biopsy speci-
mens, in accordance with the general rules of the Japan Lung
Cancer Society and the Japan Society of Clinical Oncology.4–7
The antitumor effect was evaluated again at 3 months after
the PDT. The tumors were then classified as showing a
complete response (CR) (no microscopically demonstrable
tumor in the brushings and/or biopsy specimens over a period
of 4 weeks).4–7,21 We used fluorescence bronchoscopy
(SAFE-3000) as part of the follow-up examination after
NPe6-PDT.5,7
Patient Selection
From 2004 to 2008 at the Tokyo Medical University
Hospital, we found 64 patients with CLELC by broncho-
scopical examination using autofluorescence bronchoscopy
(SAFE-3000) because of abnormal sputum production and/or
sputum cytologic abnormalities in mass survey or follow-up
after surgical resection or PDT. All 64 patients with CLELC
received NPe6-PDT. PDT was undertaken in patients who
met the criteria for PDT after obtaining their informed con-
sent in accordance with institutional guidelines.4–7 The clin-
icopathological characteristics of the patients are listed in
Table 1. Their median age at diagnosis was 74 years (range,
67–84). All the patients were men and heavy smokers with a
smoking history of more than 30 pack-years.
Efficacy Evaluation
The antitumor effect was rated, based on endoscopic
measurement of tumor size using forceps, morphologic ob-
servation, and histopathological examination by biopsy. The
antitumor effect was rated at 2 months after PDT. Antitumor
effect was rated as CR (no demonstrable tumor for 4 weeks),
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partial response (50% or greater reduction in tumor size), no
change (less than 50% reduction or less than 25% increase in
tumor size), and progressive disease (more than 25% increase
in tumor size).
RESULTS
Clinicopathological Characteristics of the
Patients Who Underwent NPe6-PDT
The clinicopathological characteristics of the patients
with roentgenographically occult lung cancer, who under-
went PDT with NPe6, are listed in Table 1. Their median age
at the time of the diagnosis of CLELC was 74 years (range,
67–83 years). All the patients were men and were heavy
smokers with a smoking history of more than 30 pack-years.
We performed skin photosensitivity test 2 weeks after PDT,
and all patients had no photosensitivity.
MPLCs were noted in 22 patients (34.4%, 22 of 64).
Synchronous lesions were noted in 10 patients (15.6%), and
metachronous lesions were noted in 12 patients (18.8%).
Treatment for MPLC Lesions
The characteristics of the patients with MPLC lesions
are summarized in Table 2. Among these 22 patients, 10
patients underwent surgery for peripheral-type lung cancer as
their first primary lesion followed by PDT for CLELC (Ta-
bles 3 and 4), one patient underwent PDT for CELC as a
primary lesion followed by an operation for peripheral-type
lung cancer as a secondary primary lesion (Table 5), and 11
patients underwent PDT alone for MPLC lesions that were all
centrally located and roentgenographically occult lung can-
cers (Table 6).
Surgery for Peripheral-Type Lung Cancer as
Their First Primary Lesion Followed by PDT for
CLELC
Ten patients underwent surgery (nine lobectomies and
one pneumonectomy) for primary lung cancer at peripheral
sites and then underwent NPe6-PDT for the treatment of
secondary primary CLELCs (Table 3).
Information on 10 Patients Who Underwent
Surgery Followed by PDT
Information on 10 patients, who underwent surgery
(nine lobectomies and one pneumonectomy) for peripheral-
type lung cancer as a first primary lesion and were then
treated for CLELCs as secondary primary lung cancers, is
presented in Table 4. The age distribution ranged from 63 to
70 years at the time of PDT for the treatment of secondary
primary CLELCs. Two of these lesions (case 3 and case 6)
were synchronous and eight were metachronous, and the
interval between the diagnosis of the first and second cancers
in this series ranged from 4 to 126 months (mean, 30 months).
After operation, eight metachronous CLELCs were found by
sputum cytology and bronchoscopical examination using
autofluorescence bronchoscopy (SAFE-3000). Histologic ex-
amination of the surgically removed tumors before PDT
revealed one adenocarcinoma, six squamous cell carcinomas,
and one small cell carcinoma (Tables 3 and 4). In case 1, a
left lower lobectomy was performed, and the pathologic
diagnosis was adenocarcinoma (p-T1N0M0 stage IA); 72
months later, a CLELC was detected in the left main bron-
chus and PDT was performed. In case 2 and case 5, the
pathologic stage was IIB (p-T2N1M0, squamous cell carci-
noma); in case 10, the pathologic stage was IIIA (small cell
carcinoma). In only one case (case 10), chemotherapy was
performed after a right lower lobectomy. No evidence of
metastasis or local recurrence was observed after the opera-
tion for the first primary lung cancer. In these 10 patients, the
secondary tumors, all of which were roentgenographically
occult, carcinoma in situ squamous cell carcinomas, were
treated with NPe6-PDT. Three lesions were located in the
trachea, and seven lesions were located in the segmental
bronchus. In all 10 patients with CELCS, a CR was achieved
after NPe6-PDT treatment (CR: 100%), and all the patients
were alive at the time of writing.
TABLE 1. Clinicopathological Characteristics of the Patients
Who Underwent NPe6-PDT (July 2004–July 2008)







Positive 64 (30 pack-years)




TABLE 2. Treatment for Multiple Lung Cancer Lesions (July
2004–July 2008)
Treatment No. of Patients (Metachronous)
Surgery PDT 10 (8)
PDT surgery 1 (1)
PDT alone 11 (3)
Total 22 (11)
PDT, photodynamic therapy.
TABLE 3. Surgery Followed by PDT (July 2004–July 2008)
Treatment No. of Patients (Metachronous)
Surgery PDT 10 (8)
Lobectomy
Adenocarcinoma 1 (1)
Squamous cell carcinoma 7 (6)
Small cell carcinoma 1 (1)
Pneumonectomy
Squamous cell carcinoma 1 (1)
PDT, photodynamic therapy.
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Figure 1 shows case 4, a patient with metachronous
double primary lung cancers. A 70-year-old man presented with
coughing and hemoptysis. He had undergone a right upper
lobectomy for squamous cell carcinoma 39 months previously.
A chest CT scan revealed a clear lung field, and no mediastinal
lymphadenopathy or abdominal lesions. A sputum cytologic
examination revealed class V, squamous cell carcinoma. Con-
ventional white-light bronchoscopy showed a 1.0 cm, thickened-
type, roentgenographically occult lung cancer at the bifurcation
between the right B6 and the basal bronchus that was identified
as a secondary primary squamous cell carcinoma (Figure 1B).
Four hours after the administration of NPe6 (40 mg/cm2), we
observed red fluorescence from the tumor using autofluores-
cence bronchoscopy (SAFE-3000) and were able to determine
the tumor margin using a photodynamic diagnosis (Figure 1C);
PDTwas then performed using a diode laser (664 nm, 100J/cm2,
150 mW) as previous reports.4,5,7
PDT for CELC as a Primary Lesion Followed by
Surgery for Peripheral-Type Lung Cancer as a
Secondary Primary Lesion
One patient underwent NPe6-PDT for a roentgeno-
graphically occult first primary lung cancer located at the
bifurcation between the left upper and lower bronchus, and
the metachronous lesion was resected by surgery (Table 5).
This patient was followed using chest CT and sputum cytol-
ogy, and 25 months later, a contralateral metachronous lesion
(adenocarcinoma) was detected as a secondary primary lung
cancer in the right S3 (Tables 2 and 5). The patient received
a right upper lobectomy and then underwent chemotherapy
because the pathologic stage was IIIA (T1N2M0) (Table 5).
PDT Alone for MPLC Lesions That Were All
Centrally Located and Roentgenographically
Occult Lung Cancers
In Table 6, the cases of multiple CLELCs that were
treated with PDT alone are summarized. In 11 of the 22
patients, MPLCs (28 lesions in total) were observed. All
lesions were roentgenographically occult lung cancers found
by abnormal sputum production and were treated using
NPe6-PDT alone (Tables 2 and 6). Seven patients had two
roentgenographically occult lung cancer lesions, three pa-
tients had three lesions, and one patient had five lesions.
Three of the 11 patients had metachronous occult lung cancer
lesions and were followed using bronchoscopical examina-
tion with conventional and autofluorescence bronchoscopy
after undergoing PDT (Tables 2 and 6). A CR was achieved
in all 11 patients with a total of 28 roentgenographically
occult lung cancer lesions (CR rate, 100%, 28 of 28); all the
patients were alive at the time of writing.
Figure 2 shows a case with five CLELCs that were
identified as metachronous MPLCs and treated using NPe6-
PDT alone. This 65-year-old man with multiple CLELCs was
diagnosed based on positive sputum cytologic findings per-
formed during a mass screening. The performance status of
this patient was 1 because of hemiparalysis caused by a
cerebral infarction. All roentgenographic examinations were
negative. The first tumor was a nodular-type early lung
cancer located in the left B3, and NPe6-PDT was performed.
TABLE 4. Surgery Followed by PDT (July 2004–July 2008)
Age (yr) Operation Pathology Interval (mo) PDT Lesion PDT Outcome
63 LL lobectomy IA (adenocarcinoma) 72 Lt. main br. CR Alive
63 LL lobectomy IIB (sq.) 10 Rt. B1 CR Alive
68 LL lobectomy IA (sq.) 0 Rt. B3 CR Alive
70 RL lobectomy IA (sq.) 39 Rt. B6-basal CR Alive
64 Lt. pneumonectomy IIB (sq.) 17 Lt. main br. CR Alive
66 RU lobectomy IA (sq.) 0 Rt. B6 CR Alive
67 RU lobectomy IA (sq.) 49 Trachea CR Alive
69 RU lobectomy IA (sq.) 4 Lt. B3 CR Alive
70 RL lobectomy IA (sq.) 43 Trachea CR Alive
65 RL lobectomy IIIA (small) 126 Rt. B1 CR Alive
PDT, photodynamic therapy; RU, right upper; LL, left lower; CR, complete response; Rt, right; Lt, left.
TABLE 5. PDT Followed by Surgery (July 2004–July 2008)
Age (yr) Lesion PDT Interval (mo) Operation Pathology Outcome
57 Lt. upper-lower CR 25 RU lobectomy IIIA (adenocarcinoma) Alive
PDT, photodynamic therapy; CR, complete response; RU, right upper; Lt, left.
TABLE 6. PDT Alone for Multiple Primary Lung Cancers
(July 2004–July 2008)
No. of Lesions Patients (Metachronous) Lesions CR Outcome
Two 7 (2) 14 14 Alive: 7
Three 3 (0) 9 9 Alive: 3
Five 1 (1) 5 5 Alive: 1
Total 11 (3) 28 28 Alive: 11
PDT, photodynamic therapy; CR, complete response.
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Eight months after the PDT, a second tumor at the bifurcation
between the right middle lobe bronchus and the basal bron-
chus was found, and the third tumor was found at the
bifurcation between the right B6 and the basal bronchus
during a routine bronchoscopic examination. Twenty months
after the first PDT, a fourth tumor was detected in the right
upper bronchus, and 29 months after the first PDT, a fifth
tumor was detected in the left B5. These five lesions were
thickened-type, roentgenographically occult lung cancers and
were all treated using NPe6-PDT. All five metachronous
lesions were completely cured using PDT, and a CR was
achieved. No evidence of metastasis or recurrence was noted.
DISCUSSION
The criteria for MPLC were first proposed by Warren
and Gates24 in 1932. The most recent and recognized criteria
FIGURE 1. A, A schema of a 70-year-old man
with metachronous multiple primary lung cancer.
He underwent a right upper lobectomy for squa-
mous cell carcinoma at S3. Thirty nine months
later, centrally located early lung cancer was de-
tected. B, Fiberoptic bronchoscopy revealed a
thickened lesion. A thickened-type squamous cell
carcinoma can be visualized at the bifurcation be-
tween right B6 and basal bronchus . C, Photo-
dynamic diagnosis using SAFE-3000 system and
NPe6 was conducted before the PDT. The red flu-
orescence excited by the diode laser (408 nm)
from the SAFE-3000 system revealed the cancer-
ous lesion .
FIGURE 2. A 65-year-old man with metachro-
nous multiple primary lung cancers. Fiberoptic
bronchoscopy revealed five thickened-type le-
sions. First cancer lesions located at the left B3
( 1), second lesion at the bifurcation between
the right middle lobe bronchus and the basal
bronchus ( 2), third lesion at the bifurcation
between the right B6 and the basal bronchus
( 3), fourth lesion at the right upper bron-
chus ( 4) and fifth lesion at left B5 ( 5). All
five metachronous lesions were completely
cured using PDT, and a CR was achieved.
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for differentiating between MPLC and recurrences are those
reported by Martini and Melamed.18 MPLC is not uncom-
mon, and several authors have recently reported an incidence
of 0.2 to 20%.12–17 Johnson et al.12,13 reported that the risk of
developing a second lung cancer was 2 to 14% per patient per
year, and that the risk increased twofold to sevenfold at 10
years after initial diagnosis. Nevertheless, no guidelines have
detailed recommendation for the selection and treatment of
patients with synchronous or metachronous MPLC. More-
over, CLELCs, which are roentgenographically occult and
can be treated using PDT, cannot be detected using high-
resolution computed tomography HRCT.4,5,25–27 Fujimura et
al.11 reported that in 236 patients with roentgenographically
occult lung cancers, a second primary lung cancer lesion was
detected in 50 patients (22%), and 13 of these 50 patients had
a third primary lung cancer lesion, whereas six of these 13
patients had a fifth primary lung cancer lesion. In an analysis
of the Mayo Lung Project, only 54 patients with CLELC were
identified, and synchronous lesions were found in four pa-
tients (7%).2,28 Our results showed that multiple primary
CLELCs were detected in 22 patients (34%, 22 of 64),
providing an incidence rate that was higher than in previous
reports (Table 1). We hypothesized that the incidence of
MPLCs might have increased not only as a result of HRCT
but also as a result of sputum cytologic examinations and
bronchoscopical examination using fluorescence bronchos-
copy, especially among patients with long history of smoking
who have undergone surgery for peripheral lung cancers. In
this report, eight patients (8 of 64, 11%) with roentgeno-
graphically occult secondary primary lung cancers were di-
agnosed based on sputum cytologic examinations, and their
lesions were detected using autofluorescence bronchoscopy
after surgical resection for peripheral-type lung cancer.
In 11 patients (11 of 64, 11%), multiple CLELCs were
detected using routine bronchoscopical examination. These
patients were all heavy smokers (more than 30 pack-years).
The incidence of multiple primary CLELCs was similar to
that in previous reports.11,29 As shown Table 4, in case 1, a
left lower lobectomy was performed because of peripheral-
type lung cancer (adenocarcinoma) and 72 months later, a
CLELC was found by abnormal sputum productions. These
results suggest that for heavy smokers, there may be higher
rate of incidence of squamous cell carcinoma as metachro-
nous cancer compared with nonsmokers.
For heavy smokers with adenocarcinoma, who undergo
surgery for primary lung cancer, sputum cytologic examina-
tions should be a required part of their follow-up.13,30,31
Careful follow-up using HRCT and sputum cytologic exam-
ination or fluorescence bronchoscopical examination might
also be recommended, as suggested by the case history of
patient 1 (Table 4). From our data, postoperative follow-up
examinations should consider the incidence of MPLCs at
peripheral or central sites in heavy smokers.
For synchronous or metachronous MPLCs, the perfor-
mance of a pneumonectomy is a predictor of poor long-term
survival, and a pneumonectomy should be avoided whenever
possible.15,16 Moghissi and Dixon32 reported that PDT cured
synchronous CLELCs 17 years after a pneumonectomy, and
they concluded that PDT can enable long-term survival and
serve as a potential cure for MPLCs. We also performed PDT
for metachronous lung cancer 17 months after a left pneu-
monectomy, and the patients was still alive at the time of
writing (Table 4). Moreover, as shown Figure 2, PDT cured
all five MPLCs in another patient, enabling the patient’s
cardiopulmonary function to be preserved (Figure 2).
No guidelines detailing recommendations for the treat-
ment of patients with MPLC have been published. Our
present results suggest that minimally invasive treatments,
such as PDT, should be performed for CLELCs of a synchro-
nous or metachronous nature. Moreover, in heavy smokers
who undergo surgery for lung cancer, sputum cytologic
examination should be a necessary component of their fol-
low-up care.
In conclusion, PDT is useful for extending the thera-
peutic options and improving the prognosis of patients with
MPLCs. In particular, for patients with long-term history of
smoking after surgical resection, careful follow-up with due
consideration of the incidence of metachronous primary lung
cancers is recommended, and PDT might play an important
role for the treatment strategy for MPLC.
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